Press release
Leading Companies Reinforcing Their Presence in the Neuroblastoma Market
Neuroblastoma Market
Neuroblastoma Market Size Looking Ahead to 2030
The neuroblastoma market is projected to expand considerably, expected to reach a value of $4.12 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 5.5% during the forecast period. The market's upward trajectory is supported by several factors, including increased research into targeted therapies, greater investments in cell therapy products, broader adoption of precision oncology techniques, and advancements in pediatric immunotherapy. Additionally, improvements in advanced diagnostic imaging are enabling earlier detection, further driving market expansion. Key trends anticipated during this period include rising use of immunotherapy vaccines for pediatric cancers, increased development of monoclonal antibody treatments, growth in cell therapy and regenerative oncology, and heightened focus on early diagnosis and symptom management.
Download a free report of the neuroblastoma market report:
https://www.thebusinessresearchcompany.com/report/neuroblastoma-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Leading Companies Influencing the Neuroblastoma Market
Several prominent organizations are making a significant impact in the neuroblastoma field. These include Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., and Provectus Biopharmaceuticals Inc. A notable industry development occurred in September 2024 when Ligand Pharmaceuticals Inc., headquartered in the United States, acquired Austria-based Apeiron Biologics AG for $100 million. This acquisition not only provides Ligand with royalty rights to Qarziba but also strengthens its commercial royalty portfolio by adding a high-value immunotherapy targeting high-risk neuroblastoma. The move aims to generate predictable, long-term revenue streams from a diversified range of key products.
Trends Shaping the Neuroblastoma Industry's Future
Companies involved in the neuroblastoma market are increasingly focusing on integrating advanced robotic technologies to enhance automation and overall operational efficiency. These robotic-enabled systems, equipped with sensors and intelligent control modules, help streamline workflows and improve traceability in sterile processing and surgical environments. For example, in April 2024, Aesculap Inc., a US-based provider of sterile-processing solutions, launched the AESCULAP Aicon RTLS. This system pairs sterilizable Bluetooth beacons with the Aicon Sterile Container System to enable continuous, automated tracking of surgical instrument trays through sterilization, storage, and operating room processes. By reducing manual errors and boosting real-time visibility of instrument status and location, the technology supports more precise operations and facilitates better clinical decision-making.
View the full neuroblastoma market report:
https://www.thebusinessresearchcompany.com/report/neuroblastoma-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Neuroblastoma Market Segmentation and Forecast Overview
This report segments the neuroblastoma market by product type, treatment type, distribution channel, and end-user. Product type categories include tablets, vaccines, and other product forms. Treatment type divisions cover chemotherapy, immunotherapy, and other treatments. Distribution channels are separated into online and offline platforms, while end-users primarily consist of hospitals and clinics. Further subsegments specify types of tablets such as oral chemotherapy and targeted therapy tablets; vaccine categories including immunotherapy and therapeutic vaccines; and other products like injectable drugs, monoclonal antibodies, and cell therapy products. This detailed segmentation provides a comprehensive view of market dynamics and future growth opportunities within the neuroblastoma industry.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leading Companies Reinforcing Their Presence in the Neuroblastoma Market here
News-ID: 4483500 • Views: …
More Releases from The Business Research Company
Construction Schedule Software Market Outlook Signals Expansion To $2.29 Billion …
The construction schedule software sector has seen significant growth in recent years, driven by increasing demands for efficient project management in the construction industry. As construction projects become more complex and digital transformation accelerates, this market is set to continue expanding steadily over the coming decade. Let's explore the market size, key players, current trends, and segmentation to get a clear picture of what lies ahead.
Steady Rise in Construction Schedule…
Confidential-Compute Display-Server Market Report 2026 Market Outlook Supported …
The confidential-compute display-server market is experiencing remarkable growth driven by the increasing need for secure remote work environments and robust data protection. As cyber threats become more sophisticated, enterprises are turning to advanced virtualization and cloud technologies to safeguard sensitive information. This analysis explores the current market size, key players, emerging trends, and detailed segmentation of this rapidly evolving industry.
Forecasted Expansion of the Confidential-Compute Display-Server Market
The confidential-compute display-server…
Compute Express Link (CXL) Memory-Appliance Market Insights Highlight Segment Ex …
The Compute Express Link (CXL) memory-appliance market has witnessed remarkable growth in recent years, driven by rapid advancements in data-intensive technologies and increasing demand for enhanced computing performance. As industries increasingly rely on sophisticated memory solutions to support AI, machine learning, and cloud infrastructures, the market is set for substantial expansion in the coming years. Let's explore the current market size, key players, emerging trends, and segmentation to understand the…
Configuration Management Software Market Report Examines Leading Companies And G …
The configuration management software market is witnessing remarkable growth as organizations increasingly seek efficient ways to handle complex IT environments. With evolving technological demands and expanding cloud adoption, this sector is set for significant expansion through 2030. Let's explore the current market size, key drivers, leading companies, and emerging trends shaping the future of configuration management software.
Configuration Management Software Market Size and Growth Outlook
The configuration management software market…
More Releases for Neuroblastoma
Pediatric Relapsed & Refractory Neuroblastoma Market Trades 2034
Market Overview
The Pediatric Relapsed and Refractory Neuroblastoma Market is expanding as unmet needs remain high for children who fail first-line therapy or experience disease recurrence. Neuroblastoma, a rare pediatric cancer originating in nerve tissues, poses significant treatment challenges when it becomes resistant or relapses after conventional chemotherapy, surgery, and radiation. As a result, demand for novel immunotherapies, targeted biologics, CAR-T therapies, and precision medicine is accelerating globally. Improved survival outcomes,…
Neuroblastoma Market Massive Growth opportunity Ahead
Neuroblastoma market Size, Status, and Forecast for the 2025-2034. In-depth research has been compiled to provide the most up-to-date information on key aspects of the worldwide market. This research report covers major aspects of the Neuroblastoma Market including drivers, restraints, historical and current trends, regulatory scenarios, and technological advancements. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The…
Pediatric Neuroblastoma Treatment Market - Redefining Possibilities: Advancement …
Newark, New Castle, USA: The "Pediatric Neuroblastoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Pediatric Neuroblastoma Treatment Market: https://www.growthplusreports.com/report/pediatric-neuroblastoma-treatment-market/7681
This latest report researches the industry structure,…
Neuroblastoma Drugs Market Size, Share, Development by 2024
New report published by Global Info Research which offers insights on the Global Neuroblastoma Drugs market.
Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands, but can also develop in the neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under…
Global Neuroblastoma Treatment Market: Latest Trends and Insights 2023
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants…
Top Rated Report: Global Neuroblastoma Market
Marketresearchreports.biz has added a new research report on the "Neuroblastoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" to its collection.
DelveInsights Report, Neuroblastoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Neuroblastoma Report is to understand the market and pipeline status of the drugs…
